
    
      Subjects will be randomised in a 1:1 ratio to either treatment sequence. Subjects randomly
      assigned to treatment with SB12 or Soliris® will receive 600 mg of eculizumab IV every week
      for first 4 weeks (initial phase) and 900 mg for the fifth week, followed by 900 mg every 2
      weeks until Week 52. Subjects who are randomised to initially receive SB12 will be switched
      to receive Soliris® and subjects who are randomised to initially receive Soliris® will be
      switched to receive SB12 at Week 26.
    
  